14 completed, 3 unknown, 1 enrolling by invitation, 1 recruiting. 9 Phase 4, 3 Phase 3, 2 Not applicable, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 5, Unknown 2, Enrolling by invitation 1, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Measles Vaccine: new trials by email Literature Review of Measles Vaccine trials Research Report on Measles Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV) - Meningococcal Immunisation, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1528 | 2023-03-27 | 2026-01-21 |
| Measles and BCG Vaccines for Mother and Child BCG vaccine, Measles vaccine, Placebo - Vaccine Preventable Disease, Measles | Phase 4 | Recruiting | Bandim Health Project | 2400 | 2021-05-20 | 2024-01-19 |
| Measles Vaccination at Health System Contacts measles vaccine, Saline - Measles Vaccine, Hospital Admission | Phase 4 | Enrolling by invitation | Bandim Health Project | 5400 | 2020-01-08 | 2025-07-29 |
| Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Measles vaccine, Hepatitis-A vaccine, Varicella vaccine - Measles, Varicella | Phase 4 | Unknown | University of Witwatersrand, South Africa | 278 | 2017-04-10 | 2020-03-17 |
| Randomized Controlled Trial of Measles Vaccination Schedule Measles vaccine - MEASLES DISEASE | Not applicable | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 120 | 2017-03-14 | 2017-05-31 |
| Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children Measles vaccine, Oral polio vaccine - Measles Vaccination, Oral Polio Vaccine | Phase 4 | Completed | Bandim Health Project | 28612 | 2016-11-01 | 2024-09-03 |
| A Second Dose of Measles Vaccine (MV) in the Second Year of Life Measles vaccine - Child Mortality, Child Morbidity | Not applicable | Completed | Bandim Health Project | 3812 | 2016-10-01 | 2024-01-19 |
| Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Double viral (MR) vaccine - Rubella, Measles | Phase 1 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 30 | 2015-09-01 | 2016-06-22 |
| Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali pentavalent rotavirus vaccine (PRV), measles vaccine (MV), yellow fever vaccine (YFV) - Diarrhea Rotavirus | Phase 4 | Completed | PATH | 600 | 2014-10-01 | 2019-01-02 |
| Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix-B™ vaccine, Infanrix/Hib™ vaccine - Malaria, Malaria Vaccines | Phase 3 | Completed | GlaxoSmithKline | 705 | 2011-11-17 | 2019-07-18 |
| Additional Measles Vaccine at 4 Months of Age Measles vaccine - Measles Infection | Phase 4 | Unknown | Bandim Health Project | 2011-08-01 | 2013-11-15 | |
| Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia Measles vaccine - Measles | Completed | University of North Carolina, Chapel Hill | 203 | 2011-05-01 | 2014-09-18 | |
| Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants GSK Biological's Investigational Malaria Vaccine 257049, Engerix-B, Tritanrix HepB Hib - Malaria | Phase 2 | Completed | GlaxoSmithKline | 480 | 2011-01-13 | 2018-08-15 |
| Immunology of Non-specific Effects of Vaccine Measles vaccine - Measles, Diphtheria | Phase 4 | Completed | Bandim Health Project | 400 | 2006-01-01 | 2011-09-22 |
| Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV) - Encephalitis, Japanese B | Phase 3 | Completed | PATH | 600 | 2005-11-21 | 2020-03-10 |
| Early Two-dose Measles Vaccination Trial Measles vaccine - Measles | Phase 4 | Completed | Bandim Health Project | 5879 | 2003-07-01 | 2012-03-06 |
| Long-term Follow-up of Measles Antibodies Measles vaccine - Measles | Phase 4 | Completed | Bandim Health Project | 1960 | 2002-03-01 | 2011-09-22 |
| Ontogeny of Measles Immunity in Infants Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous), MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous) - Measles | Completed | Stanford University | 750 | 1993-07-01 | 2022-06-09 | |
| A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group Attenuvax, M-M-R-II - HIV Infections, Measles | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 270 | 2021-10-28 |
Measles (10) · Infant Death (2) · Malaria (2) · Malaria, Falciparum (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Chickenpox (1) · Diphtheria (1) · Encephalitis, Japanese (1) · HIV Infections (1) · Hepatitis A (1) · Hepatitis B (1) · Rubella (1) · Tetanus (1) · Vaccine-Preventable Diseases (1)
Bandim Health Project (8) · GlaxoSmithKline (2) · PATH (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Sanofi Pasteur, a Sanofi Company (1) · Stanford University (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · University of North Carolina, Chapel Hill (1) · University of Witwatersrand, South Africa (1)
Guinea-Bissau (8) · India (2) · South Africa (2) · United States (2) · Brazil (1) · Burkina Faso (1) · Ghana (1) · Malawi (1) · Mali (1) · Philippines (1) · Puerto Rico (1) · Zambia (1)
Ane Fisker, MD, PhD (2) · Aksel Jensen, PhD (1) · Amabelia Rodrigues, Ph (1) · Anshu Varma, MSc (1) · Carolyn B Moore, MD (1) · Chandwani S (1) · Christine Benn, DMSc (1) · Hayley Altman Gans (1) · Jose CerbinoNeto, PHD (1)
PMID 18394765, PMID 18653640, PMID 21118875, PMID 21666159, PMID 23994379, PMID 24436454, PMID 24522160, PMID 24688075, PMID 24829213, PMID 24835247, PMID 25131735, PMID 27912735, PMID 28545041, PMID 28992261, PMID 29432383, PMID 29659924, PMID 31282539, PMID 31711464, PMID 32307279, PMID 32897359, PMID 35461287, PMID 35747181, PMID 38637212
R01AI070018 (1)